The 7th CAR-TCR Summit Europe will be held in London, UK February 27-29, 2024

London UK – Cell therapy continues to transform the oncology field with advances across in vivo engineering and novel armouring enhancements, but this year has also seen the translation of cell therapies’ curative potential into the autoimmune space to capitalise on their targeting abilities. Despite investment challenges, innovation not slowing for those working in CAR-T and TCR drug development, as the mission to engineer a disease-free world remains front of mind.

Providing exclusive access to the most cutting-edge advances across pre-clinical platforms, clinical advances, and streamlined manufacturing, the 7th CAR-TCR Summit Europe is your must-attend forum to stay at the forefront of cell therapy innovations.

Joining 300+ industry experts and world-leading speaker faculty is Beacon’s Lead Research Analyst, Rachel East. Set to deliver ‘A Landscape Overview of CAR & TCR Therapies’, Rachel’s seminar promises to review the current trends in the CAR & TCR therapy landscape as well as look to the future and analyse solid tumour progress and novel non-oncology disease indications.

For further details about the summit, including registration and abstract submission, please click here.


Summit details

When: February 27-29, 2024

Where: ExCeL London – Royal Victoria Dock, 1 Western Gateway,  London E16 1XL